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ABSTRACT
The epithelial cell adhesion molecule (Ep-CAM) exhib-
ited an ovarian cancer:normal human ovarian surface epi-
thelium ratio of 444. For validation studies, real-time quan-
titative PCR analysis and immunohistochemistry were
performed in normal and malignant ovarian epithelial cell
lines and tissues. To evaluate the potential of the Ep-CAM
autoantibody as a tumor marker, we examined the amount
of Ep-CAM autoantibody in serum samples obtained from
ovarian cancer patients and normal controls by an ELISA.
Real-time quantitative PCR analysis revealed significant
overexpression of Ep-CAM mRNA in cancer cell lines (P <
0.001) and microdissected cancer tissues (P < 0.05), com-
pared with that in cultured normal human ovarian surface
epithelium and microdissected germinal epithelium, respec-
tively. Immunolocalization of the Ep-CAM autoantibody
showed that the sera of ovarian cancer patients expressed
higher levels of Ep-CAM autoantibody than benign tumor
patients and normal controls (P < 0.05). The levels of Ep-
CAM autoantibody found were as follows: 0.132 in 52 pa-
tients with ovarian cancer, 0.098 in 26 cases with benign
gynecologic disease, and 0.090 in 26 normal women. This
investigation has shown that the Ep-CAM autoantibody was
found to be associated with ovarian cancer and suggested
that future research assessing its clinical usefulness would be
worthwhile.
INTRODUCTION
Ovarian cancer has the highest mortality rate among all of
the gynecologic malignancies. Every year, 25,000 ovarian can-
cer cases are newly diagnosed in the United States, and15,000
deaths, secondary to the malignancy, occur annually (1).
Despite intense efforts with cytoreductive surgeries and
combined chemotherapeutic modalities, most advanced-stage
ovarian cancer patients experience relapses and eventually
die from disease (2). There have been continuous efforts in
developing new drugs and treatment modalities. Neverthe-
less, the prognosis for advanced and recurrent ovarian can-
cers has not substantially changed (3). More than 70% of the
patients are in stage 3 or stage 4 at the time of diagnosis (4).
In present screening modalities, transvaginal sonography can
detect early stage disease with great sensitivity, but it is
expensive and has low specificity. Although serum marker
assays could provide a less expensive and more convenient
initial screening test, the sensitivity of assays is low and
variable. Measurement of serum CA 125 with ultrasound
screening confers high specificity but detects only 60% of
early stage ovarian cancer (5). To improve survival, there-
fore, it is necessary to develop specific tumor markers that
can be used to detect early disease.
In our previous cDNA microarray study, we identified a
spot corresponding with a protein called Ep-CAM2 (6). Because
most ovarian cancers are of epithelial cell origin, deregulated
epithelial antigens may be ideal candidate markers.
A known biological role of Ep-CAM is its relationship to
homophilic cell adhesion (7). Like other adhesion molecules,
Ep-CAM is known to be involved in the signaling cascade
related to proliferation, differentiation, and apoptosis. The effect
of Ep-CAM as a regulator of cadherin-mediated functions is to
promote invasion and metastasis (8–10). However, it has also
been shown to play a role as an adhesion molecule that sup-
presses metastasis by preventing cell scattering (11). Therefore,
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Ep-CAM may have a bidirectional effect in the progression of
malignancy.
Here, we show the use of microarray technology and sub-
sequent validation studies to identify overexpression of Ep-
CAM transcript and protein in ovarian cancer cells and tissues,
and provide evidence that Ep-CAM autoantibody may be asso-
ciated with ovarian cancer.
MATERIALS AND METHODS
Cell Lines and Culture Conditions. All of the cell lines
and cultures were maintained at 37°C in a humidified 5% CO2
ambient air atmosphere. They were grown in Medium 199 and
MCDB 105 (1:1; Sigma, St. Louis, MO) supplemented with 10%
fetal bovine serum (Gemini Bio-Products, Calabasas, CA). Normal
HOSE cultures were established by scraping the surface of the
ovary, as described previously. (12) Eight normal HOSE cells used
in this experiment were HOSE 17, HOSE 36, HOSE 642, HOSE
695, HOSE 697, HOSE 713, HOSE 726, and HOSE 730. Ovarian
cancer cell lines were established either by recovery from ascites or
explanted from solid tumors as described previously. (12) Ten
ovarian cancer cell lines were used: OVCA3, OVCA420,
OVCA429, OVCA432, OVCA433, OVCA633, CAOV3, DOV13,
and ALST, as well as SKOV3. All of the cell cultures and cell lines
were established in the Laboratory of Gynecologic Oncology,
Brigham and Women’s Hospital, except OVCAR-3 and SKOV-3,
which were purchased from American Type Culture Collection
(Rockville, MD).
Tissue and Serum Samples. All of the patients were
treated at the Brigham and Women’s Hospital between 1992
and 2000. We retrieved patients with ovarian tumors with
different histological types and grades based on the WHO
and the International Federation of Gynecology and Obstet-
rics criteria. All of the patient-derived biological specimens
were collected and archived under protocols approved by the
Brigham and Women’s Human Subjects Committee or stud-
ied as an approved use of discarded human materials. All of
the tumor tissues were collected from the primary ovarian
sites from patients undergoing surgery. They contained less
than 20% of normal tissue. In this experiment, 136 primary
ovarian tumors were used.
For fresh-frozen sections, fresh specimens collected at the
operating room were placed in tissue culture medium, Medium
199 and MCDB 105 (1:1) with 10% fetal bovine serum, and
transported to the laboratory. After removing the nontumorous
tissue, the specimens were immediately embedded in Tissue Tek
OCT medium (Miles, Elkhart, IN), snap-frozen in liquid nitro-
gen, and stored at 80°C until use.
The archival tissues in paraffin blocks were collected from
pathology files in the Laboratory of Gynecologic Oncology at
the Brigham and Women’s Hospital.
Preoperative serum samples from women with ovarian
cancer and benign gynecologic disorders, and serum samples
from nondiseased normal were obtained between 1999 and
2000. These specimens were stored at 80°C without any
incident of thawing.
Laser Capture Microdissection. Tissues stored in Tis-
sue Tek OCT medium at 80°C were sectioned at 7 m in a
cryostat (Leica, Allendate, NJ). Sections were mounted on
uncoated glass slides and immediately fixed in 70% and
50% ethanol for 30 s in each, stained with H&E, dehydrated
in an increased series of alcohol, and cleared in xylene for 5
min in each microdissection. Once air-dried for 3 min, the
sections were laser microdissected with the PixCell II system
(Arctarus, CA). Morphologically normal ovarian epithelial
cells and malignant epithelial ovarian cancer cells were
procured.
Microarray Probe and Hybridization. The MICRO-
MAX human cDNA system I (NEN Life Science Products,
Inc., Boston, MA), which contains 2400 known human cDNA
on a 1  3 slide, was used in this study as described (6).
Biotin-labeled cDNA was generated from 3 g total RNA,
which was pooled from HOSE17, HOSE36, and HOSE642.
DNP-labeled cDNA was generated from 3 g total RNA that
was pooled from ovarian cancer cell lines OVCA 420, OVCA
433, and SKOV3. Before the cDNA reaction, an equal
amount of RNA controls (nonhuman RNA from Arabidopsis
and bacteria) were added to each batch of the RNA samples
for normalization. The biotin-labeled and DNP-labeled
cDNA were mixed, dried, and resuspended in 20 l hybrid-
ization buffer, which was added to the cDNA microarray and
covered with a coverslip. Hybridization was carried out over-
night at 65°C inside a hybridization cassette (Telechem, Inc.,
Sunnyvale, CA).
After hybridization, the microarray was washed with 30 ml
0.5 SSC, 0.01% SDS, and then 30 ml 0.06 SSC, 0.01%
SDS, and finally, 0.06 SSC alone. The hybridization signal
from biotin-labeled cDNA was amplified with streptavidin-
horseradish peroxidase and Cy5-tyramide, whereas hybridiza-
tion signal from DNP-labeled cDNA was amplified with anti-
DNP-horseradish peroxidase and Cy3-tyramide. After the
posthybridization wash, the cDNA microarray was air-dried and
signal amplification was detected with a laser scanner.
Laser detection of the Cy3 signal (derived from ovarian
cancer cells) and Cy5 signal (derived from HOSE cells) on
the microarray was acquired with a confocal laser reader,
ScanArray3000 (GSI Lumonics, Watertown, MA). Separate
scans were taken for each fluor at a pixel size of 10 m.
cDNA derived from the control RNA hybridized to 12 spe-
cific spots within the Microarray. Cy3 and cy5 signals from
these 12 spots should theoretically be equal and were used to
normalize the different efficiencies in labeling and detection
with the two fluors. The fluorescence signal intensities and
the Cy3:Cy5 ratios for each of the 2400 cDNAs were ana-
lyzed by the software Imagene 3.0 (Biodiscovery Inc., Los
Angeles, CA).
Real-Time Quantitative Reverse Transcription-PCR.
Total RNA extraction and cDNA synthesis were performed as
described previously (13). mRNA was extracted from normal
ovarian epithelial cell cultures (HOSE 695, HOSE 697, HOSE
713, HOSE 726, and HOSE 730), ovarian carcinoma cell lines
(OVCA3, OVCA420, OVCA429, OVCA432, OVCA433,
OVCA633, CAOV3, DOV13, SKOV3, and ALST), 3 normal
ovarian epithelial tissues, and 13 ovarian cancer tissues.
Real-time PCR was performed in duplicate using primer
sets specific for Ep-CAM (forward primer: 5-CGTCAAT-
GCCAGTGTACTTCAGTTG-3; reverse primer: 5-TCC-
AGTAGGTTCTCACTCGCTCAG-3) and a housekeeping
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gene, GAPDH, in an ABI PRISM 5700 Sequence Detector.
cDNA was generated from 1 g total RNA using the TaqMan
reverse transcription reagents containing 1 TaqMan reverse
transcription buffer, 5.5 mM MgCl2, 500 M dNTP, 2.5 M
random hexamer, 0.4 units/l RNase inhibitor, and 1.25
units/l MultiScribe reverse transcriptase (PE Applied Bio-
systems, Foster City, CA) in 100 l. The reaction was incu-
bated at 25°C for 10 min, 48°C for 30 min, and finally at
95°C for 5 min. A total of 0.5 l of cDNA was used in a 20
l PCR mix containing 1 SYBR PCR buffer, 3 mM MgCl2,
0.8 mM dNTP, and 0.025 units/l AmpliTaq Gold (PE Ap-
plied Biosystems). Amplification was then performed with
denaturation for 10 min at 95°C, followed by 40 PCR cycles
of denaturation at 95°C for 15 s and annealing/extension at
60°C for 1 min. The ABI5700 system software monitored the
changes in fluorescence of SYBR Green I dye in every cycle,
and the threshold cycle for each reaction was calculated as
described (13).
Immunohistochemistry. Specimens used in this experi-
ment consisted of 5 normal ovaries, 17 benign ovarian tumors,
52 borderline ovarian cancers (29 serous, 21 mucinous, 1 endo-
metrioid, and 1 clear cell), and 67 invasive ovarian cancers (31
serous, 20 mucinous, 12 endometrioid, and 4 clear cell).
Immunostaining was performed by the avidin-biotin
method, as described previously (13). Sections were incu-
bated with mouse monoclonal antibody GA733 against Ep-
CAM (2.35 g/ml, 1:100 dilution; DAKO, Carpinteria, CA)
for 60 min at room temperature. The negative control sec-
tions were treated in parallel but incubated with normal
mouse serum instead of the primary antibodies. All of the
sections were incubated in a moist chamber. Sections were
then incubated with a biotinylated goat antimouse IgG anti-
body for 30 min (Vector Laboratories, Burlingame, CA).
After incubation in avidin-biotin complex (Vector Laborato-
ries) for 30 min, the reaction product was visualized by
3,3-diaminobenzidine tetrahydrochloride (Vector Laborato-
ries). Finally, sections were dehydrated in ethanol, cleared in
xylene, and mounted in SP15–500 Permount (Fisher Scien-
tific).
Representative photomicrographs were recorded by a
digital camera (Optronics, Goleta, CA). To evaluate the re-
sult, we established a score corresponding to the sum of both
staining intensity (strong positive staining in most of cells,
3; moderate staining in cells, 2; weak staining in cells,
1; and no evidence of staining, 0), and percentage of
positive cells (most of cells demonstrating staining, 3; half
of cells demonstrating staining, 2; few cells demonstrating
staining, 1; and no cells staining, 0), as described (14).
Differences between groups were evaluated by the sum of
intensity and cell count score. The slides were scored in the
absence of any clinical data, and the final score reported was
the average of the three observers.
ELISA. ELISA performed Immunodetection of Ep-
CAM autoantibody, as described (15). Flat-bottomed micro-
titer ELISA plates ( Diagnostic, San Antonio, TX) were
incubated at 4°C overnight with 100 l purified Ep-CAM
(2.5 g/ml), purified with monoclonal antibody GA 733 as
described (16), in 0.05 M carbonate buffer (pH 9.7). After
washing three times with 5 mM Tris buffer (pH 7.8) with
0.15 mol of NaCl, 1 mmol of MgCl2 and 8 mM of sodium
azide, the wells were blocked for 1 h at 37°C with 200 l 50
mmol/liter Tris buffer (pH 7.8) with 10 g of BSA/liter and
washed three times. Serum samples were diluted 1:50 in 50
mmol/liter Tris Buffer (pH 7.8) with 60 g BSA and 0.5 g of
sodium azide, and incubated overnight at 4°C. After washing
six times, the wells were incubated for 2 h at room temper-
ature with 100 l horseradish peroxidase-conjugated goat
antihuman IgG (Pierce, Rockford, IL) diluted 1:20,000 in 50
mmol/liter Tris buffer (pH 7.8) containing 60 g of BSA and
0.5 g of sodium azide/liter. After washing six times, 100 l
Fig. 1 Microarray analysis using
pooled RNA isolated from 3 nor-
mal HOSE cultures and 3 ovarian
cancer cell lines. Arrows indicate
spots on two microarrays, which
correspond to Ep-CAM.
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TMB (3,3,5.5-tetramethyl-benzidine) substrate solution (
Diagnostic) was added for development at room temperature
for 15 min. After the addition of stop solution, the absorbance
at 450 nm was measured by an automatic ELISA reader
(Bio-Rad, Hercules, CA).
The CA 125 assay was performed by an immunoradiomet-
ric assay according to the manufacturer’s instructions (Abbot
Diagnostics).
Results were expressed as the mean absorbance of tripli-
cate wells after subtraction of background values. Negative
controls include the elimination of purified Ep-CAM, patient
serum, secondary antibody, or substrate for development in the
assay.
Statistical Analysis. Data were mainly summarized as
mean, SD, 95% CI, or range. Mann-Whitney U test was used to
test statistical significance in real-time PCR. Immunohisto-
chemistry and ELISA were tested by one-way ANOVA and
Turkey’s multiple comparison tests among groups.
To obtain the cutoff values, we performed ROC analysis.
In cases of combined cutoff vale, the result of the logistic
analysis using both Ep-CAM and CA 125 was used.
Sensitivity and specificity for serum samples were esti-
mated nonparametrically with binomial point estimates and ex-
act 95% CIs. Differences between two sensitivities (or specific-
ities) on the same subjects were evaluated for significance with
McNemar’s test. Partial correlation coefficients adjusted by age
were calculated between CA 125 and Ep-CAM autoantibody.
The level of critical significance was assigned at P 	 0.05.
All of the analyses were performed using SPSS version 9.0
(SPSS Inc., Chicago, IL).
RESULTS
Using RNA isolated from 3 normal HOSE cell lines and 3
ovarian cancer cell lines, we identified 30 genes with Cy3:Cy5
ratios 
5 (5). One of these, with a Cy3:Cy5 ratio of 444,
corresponded to a tumor-related protein called Ep-CAM. It is
selectively illustrated in Fig. 1.
To validate the expression of Ep-CAM, real-time PCR
was applied to an expanded series of ovarian cancer cell lines
and tissues. On the basis of the CT relative to the normal
cell line, HOSE 697, the expression of Ep-CAM in a variety
of cell lines was calculated. There was a highly significant
difference in the expression of Ep-CAM between 5 normal
ovarian epithelial cell lines and 10 ovarian cancer cell lines
(P 	 0.001). The mean  SD of normal and cancer cell lines
were 2.63  1.79 and 4265.61  2522.14, respectively.
Except for DOV13, the expression of EP-CAM in the other
ovarian cancer cell lines was 1000-fold greater than that in
HOSE 697 (Fig. 2A).
Ep-CAM expression in ovarian cancer tissues was also
examined. We found a significant difference between the 3
normal ovarian surface epithelia and 13 ovarian cancer tissues
(P 	 0.05). The mean  SD of the two groups was 1.68  0.75
and 140.92  277.91, respectively. (Fig. 2B). Ep-CAM immu-
noreactivity was not observed in the stroma of any of the
specimens examined. Positive staining was mainly localized to
the cellular membrane and cytoplasm of epithelial cells (Fig. 3).
The mean (and 95% CI) of immunostaining scores in
normal ovary, benign ovarian tumor, borderline ovarian tumor,
and invasive ovarian cancer were 0.80 (95% CI, 0.00–2.16),
Fig. 2 A, relative quantitation of Ep-
CAM mRNA in normal and malignant ep-
ithelial ovarian cancer cell lines. Statisti-
cally significant difference was obtained
between normal (HOSE 695, HOSE 697,
HOSE 713, HOSE 726, and HOSE 730)
and cancer cell lines (ALST, CAOV3,
DOV13, OVCA3, OVCA 420, OVCA429,
OVCA432, OVCA433, and OVCA633)
by Mann-Whitney U test (P 	 0.001). B,
relative quantitation of Ep-CAM mRNA in
normal and malignant ovarian cancer tis-
sues. Statistically significant difference
was obtained between normal (756HOSE,
757HOSE, and 763HOSE) and cancer tis-
sues (330A, 333A, 426C, 427A, 466A,
489C, 629A, 683A, 690C, 720C, 721C,
734A, and 834A) by Mann-Whitney U test
(P 	 0.05). Each value was expressed as
the mean of duplicate determinations;
bars, SD.
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1.76 (95% CI, 1.07–2.46), 3.74 (95% CI, 3.27–4.21), and 3.34
(95% CI, 2.99–3.70), respectively. This difference among
groups was statistically significant (P 	 0.001). There was no
statistical difference between borderline tumors and invasive
cancers (P  0.174; Table 1).
In the cancer group, no difference in Ep-CAM immunore-
activity among different histological types and grades was ob-
served. It appeared that mucinous borderline cases represented
relatively higher Ep-CAM expression, however, compared with
any other cancer groups. Stage III and IV cases showed lower
Ep-CAM expression, compared with stage I cases (P 	 0.01;
Table 1).
We examined the autoantibody of Ep-CAM by ELISA in
sera of 26 normal controls, 26 patients with benign ovarian
disease, and 52 ovarian cancer patients by ELISA. Normal
controls matched for age with patients with benign ovarian
disease and ovarian cancer with a mean age of 58 years old
(range, 45–76). Reciprocal serum end point dilutions ranged
between 10 and 1000 among 3 cancer patients (Fig. 4). The
schematic results are shown in Fig. 5. The mean (and 95% CI)
of Ep-CAM autoantibody levels in normal controls, benign
ovarian disease, and cancer patients were 0.090 (95% CI,
0.080–0.100), 0.098 (95% CI, 0.088–0.108), and 0.132 (95%
CI, 0.123–0.141), respectively. The difference between cancer
cases and the other cases was statistically significant (P	 0.05).
In cancer patient serum, there were no significant difference in
histological types and grades. The sera of stage IV cases showed
lower levels of Ep-CAM autoantibody, compared with either
stage I or II (P 	 0.05; Table 2).
On the basis of the cutoff value as 0.140, which was
defined as an absorbance 
2 SDs above the mean value of the
normal controls, 22 ovarian cancer cases (42.3%) were positive,
whereas none of the control (0%) and 2 benign ovarian disease
(7.7%) cases were positive.
We plotted a ROC to investigate optimal cutoff values
and to compare Ep-CAM autoantibody with CA 125. On the
Fig. 3 Immunolocalization of
Ep-CAM in normal and malig-
nant ovarian tissues. A, normal
ovarian surface epithelial cells
(arrowheads); B, benign serous
cystadenoma; C, serous border-
line tumor; D, serous cyst-
adenocarcinoma; E, mucinous
borderline ovarian tumor; F,
mucinous cystadenocarcinoma;
G, endometrioid cystadenocar-
cinoma; H, clear cell cystade-
nocarcinoma. Scale bar repre-
sents 50 mm.
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basis of the cutoff value as 0.115, 38 ovarian cancer cases
(73.1%) were positive, whereas 5 normal (19.2%) and 6
benign ovarian disease cases (23.1%) were positive. Data
obtained from Ep-CAM autoantibody screening showed a
sensitivity of 73.1% (95% CI, 61.0 – 85.2), and a specificity
of 80.8% (95% CI, 65.7–95.9). CA125, for which the cutoff
value is 35 units/ml in accordance with the supplier, showed
a sensitivity of 86.5% (95% CI, 77.2–95.8) and a specificity
of 88.5% (95% CI, 76.2–99.8) in this experiment. By area
test of ROC curve, significant difference was found between
CA 125 (0.965; 95% CI, 0.932– 0.998) and Ep-CAM autoan-
tibody (0.851; 95% CI, 0.769 – 0.934; P 	 0.05; Fig. 6). A
patient with positive Ep-CAM autoantibody has 11.4-fold
risk of normal women in the diagnosis of ovarian cancer
(odds ratio  11.4; 95% CI, 3.6 –36.1; relative risk  3.8) in
comparison with CA 125 (odds ratio  49.3; 95% CI, 11.6 –
208.6; relative risk  7.5). We also plotted the ROC curve in
using both Ep-CAM autoantibody and CA 125.
Fig. 7 displays a bivariate plot of Ep-CAM autoantibody
versus CA 125 for normal control subjects and epithelial ovarian
cancer cases. From the results of the multiple logistic analysis
using both Ep-CAM autoantibody and CA 125, the combined
cutoff line was 5.23 33.84Ep-CAM0.04CA 125, which
gave the sensitivity 47 of 52  90.4% (95% CI, 82.4% 
98.4%) and specificity 24 of 26  92.3% (95% CI, 82.1% 
100%), respectively.
Table 1 The expression of Ep-CAM in relation to histopathologic characteristics in normal ovary, benign ovarian tumor, borderline ovarian
tumor, and invasive ovarian cancer in immunohistochemical study
Characteristics No. Scoresa 95% CIb Range Tc Pd
All subjects 141 3.17 2.88 to 3.46 0–6
Diagnostic category
Normal 5 0.80 0.00 to 2.16 0–2 a P 	 0.001
Benign 17 1.76 1.07 to 2.46 0–4 b
Borderline 52 3.74 3.27 to 4.21 0–6 c
Invasive 67 3.34 2.99 to 3.70 0–6 c
Histology of cancer
Serous 60 3.36 2.99 to 3.72 0–4 P  0.32
Mucinous 41 3.88 3.32 to 4.43 0–6
Endometrioid 13 3.31 2.44 to 4.18 0–5
Clear cell/other 5 3.00 0.37 to 5.63 0–6
Tumor differentiation
Borderline 51 3.65 3.15 to 4.16 0–6 P  0.61
Well 26 3.83 3.23 to 4.42 0–6
Moderate 14 3.29 2.40 to 4.18 0–5
Poor 28 3.36 2.86 to 3.85 0–6
FIGO stage
I 54 4.11 3.72 to 4.49 2–6 a P  0.007
II 8 4.33 2.90 to 5.77 2–6 a, b
III 43 3.20 2.68 to 3.72 0–6 b
IV 14 2.90 1.81 to 3.99 0–5 b
a Values are given as a mean.
b CI, confidence interval.
c The same letters indicate nonsignificant difference between groups based on Tukey’s multiple comparison test.
d Statistical significances were tested by ANOVA among groups.
Fig. 4 Absorbance values (mean  SD) of di-
luted sera of 3 patients against the Ep-CAM pro-
tein. Each value was expressed as the mean of
triplicate; bars, SD.
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McNemar’s test for the equality of the two sensitivity
estimates between the two marker combination and CA 125 or
Ep-CAM autoantibody alone gives a P  0.50 or P 	 0.02,
respectively, indicating a significant increase in sensitivity when
combining Ep-CAM autoantibody with CA 125 versus Ep-
CAM autoantibody alone. The simultaneous point estimate of
specificity of the combined rule for CA 125 and Ep-CAM
autoantibody increased to 92.3%. However, there was no sig-
nificant difference between the combination and CA 125 or
Ep-CAM autoantibody alone.
By the partial correlation coefficient adjusted by age, we
observe a weak correlation between CA 125 and Ep-CAM
autoantibody in all of the cases (r  0.181; P 	 0.05) and in
ovarian cancer cases (r  0.076; P  0.59), respectively.
DISCUSSION
In epithelial ovarian cancer, many tumor markers have
been identified and studied. However, most of these markers
have not shown satisfactory sensitivity and specificity, and,
therefore, are not useful as a routine screening method for
ovarian cancer. CA 125 is the most extensively researched
marker in ovarian cancer, but there is only preliminary evidence
that ovarian cancer screening using CA 125 can reduce mortal-
ity (17). Therefore, it is of paramount importance to identify
new markers, particularly serological markers, which can be
used alone or in combination with CA 125 to improve the
sensitivity and the specificity of the screening assay.
Multiple methods have been applied to identify tumor
markers. One approach is through the identification of differen-
tially expressed genes in ovarian cancer cells and normal ovar-
ian surface epithelial cells. This is achieved by validation pro-
cesses to determine whether the differentially expressed protein
can be used as a serological marker. Methods used to identify
differentially expressed genes include expression sequencing
tag sequencing, serial analysis of gene expression, differential
display PCR, and cDNA or oligonucleotide microarray analysis
(18–21). In this study, the MICROMAX cDNA microarray
system, which contains 2400 known genes with known function,
was used. This system, which requires the use of only 1 g of
total RNA, is particularly attractive when small numbers of
cells, such as normal HOSE cells, are unavoidable. Among all of
the genes analyzed, Ep-CAM showed the highest Cy3:Cy5 ratio,
suggesting that it was highly overexpressed in ovarian cancer
cells (5).
Ep-CAM is a Mr 40,000 glycoprotein encoded by the
GA733-2 gene located at chromosome 4q (22, 23). Ep-CAM
has been referred to as CO17-1A, MH99, AUA1, MOC31,
323/A3, KS1/4, GA733, HEA125 or KSA, EGP, EGP40, and
GA733-2 (22, 24 –31). GA733-1 gene product has been
known as a unique homologous protein and shares 49%
homology with the Ep-CAM amino acid sequence (22). Low
levels of Ep-CAM are detected in all of the epithelial cells
except for squamous stratified epithelium (10). Using real-
time PCR and immunohistochemistry, we also demonstrate
low levels of Ep-CAM mRNA and protein expression in
normal ovarian surface epithelial cells.
The exact biological function of Ep-CAM is still un-
known. On the basis of the presence of EGF-like repeats in
the extracellular domain, Ep-CAM was proposed to function
as a cell adhesion molecule or a cell surface receptor capable
of signal transduction (8 –10). Although the molecule is ca-
pable of mediating homophilic adhesive interactions, how-
ever, there is not sufficient evidence that EP-CAM-mediated
adhesions are required for epithelial cell support. Despite the
correlation with malignant proliferation in epithelial cancers,
Ep-CAM-mediated cell-cell adhesions prevent cell scattering
(11). This dualistic role of Ep-CAM in carcinogenesis has
required additional investigation. Similar to most epithelial-
derived cancers, ovarian cancers express significantly higher
levels of Ep-CAM than normal and benign ovarian epithelia.
We found no significant difference, however, in Ep-CAM
expression in borderline and invasive ovarian tumors with
different grades. These data suggest that Ep-CAM may be
involved in the development of both borderline and invasive
disease and may be associated with an early phase of ovarian
carcinogenesis. In contrast to ovarian cancer, other cancers
show a different relationship between Ep-CAM expression
and degree of differentiation. For example, high-grade tran-
sitional cancer of the bladder shows significantly higher
Ep-CAM expression than low-grade transitional cancer
(32,33). Furthermore, Ep-CAM was expressed at higher level
in high-grade cervical intraepithelial neoplasia than in low-
grade cervical intraepithelial neoplasia (34).
In 5 consecutive normal ovary staining, we concluded
baseline expression levels of Ep-CAM; we also found the same
result in the normal epithelium of the cancer patient slides. It is
expected that Ep-CAM expression varies dramatically in tumor
tissue samples, because ovarian tumors have different grades
and subtypes, whereas the normal surface epithelium contains a
homogenous population of epithelial cells.
It is interesting to note that stage III and IV ovarian
cancer show significantly lower Ep-CAM expression than
stage I disease. A similar pattern has been observed in
laryngeal cancer in which lower expression of Ep-CAM
correlates with a high frequency of metastases (35). Further-
more, it has been shown that transfection of murine Ep-CAM
into mouse colorectal cancer cells suppressed their metastatic
Fig. 5 Box plots of EP-CAM autoantibody levels in case patients with
normal (n  26), benign disease (n  26), and ovarian cancer (n  52).
The box is bounded above and below by the 25% and 75% percentiles,
the median is the line in the box, and the upper and lower error bars
indicate 99% of values. There is a significant difference among three
groups by ANOVA (P 	 0.05), and the differences are significant
between cancer cases and the other groups based on Tukey’s multiple
comparison test.
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potential (11). These results may be explained by the fact that
Ep-CAM also acts as an adhesion protein of which the
down-regulation may facilitate the metastasis process during
cancer progression (7).
Using an established ELISA, we evaluated the potential
of using Ep-CAM autoantibody levels to detect ovarian can-
cer. Ep-CAM autoantibody levels proved to be significantly
higher in ovarian cancer than normal and benign ovarian
disease. Although it is less sensitive and less efficient than
CA 125 as shown in this experiment (ROC curve and odds
ratio), Ep-CAM autoantibody may be complementary to CA
125 as suggested by the low correlation between the two.
Using the combination of Ep-CAM autoantibody and CA
125, we found that the specificity was increased as compared
with CA 125 alone without lowering the sensitivity. Conse-
quently, it may be valuable to use Ep-CAM autoantibody in
ovarian cancer screening. Furthermore, considering that there
was no expression difference in patient sera between early
and advanced disease, it may be possible to increase early
Table 2 Preoperative Ep-CAM autoantibody levels by selected characteristics of case patients with ovarian cancer and control subjects without
ovarian cancer
Characteristics No. Absorbancesa 95% CIb Range Tc Pd
All subjects 104 0.113 0.106 to 0.120 0.054–0.203
Diagnostic category
Normal 26 0.090 0.080 to 0.100 0.054–0.133 a P 	 0.001
Benign disease 26 0.098 0.088 to 0.108 0.055–0.154 a
Ovarian cancer 52 0.132 0.123 to 0.141 0.080–0.203 b
Histology of cancer
Serous 26 0.126 0.112 to 0.139 0.081–0.203 P  0.083
Mucinous 10 0.129 0.116 to 0.141 0.104–0.149
Endometrioid 10 0.151 0.143 to 0.178 0.139–0.201
Clear cell/others 6 0.120 0.087 to 0.153 0.080–0.147
Tumor differentiation
Borderline 8 0.119 0.104 to 0.133 0.093–0.136 P  0.061
Well 6 0.163 0.132 to 0.194 0.141–0.201
Moderate 12 0.135 0.120 to 0.150 0.104–0.166
Poor 26 0.128 0.114 to 0.142 0.080–0.203
FIGO stage
I 16 0.137 0.120 to 0.153 0.093–0.201 a
II 6 0.150 0.105 to 0.195 0.108–0.203 a
III 26 0.131 0.120 to 0.142 0.081–0.166 a, b P  0.039
IV 4 0.094 0.068 to 0.120 0.080–0.108 b
a Values are given as a mean.
b CI, confidence interval.
c The same letters indicate nonsignificant difference between groups based on Tukey’s multiple comparison test.
d Statistical significances were tested by ANOVA among groups.
Fig. 6 ROCs curves of Ep-CAM autoantibody (A), CA 125 (B), and
Ep-CAM autoantibody and CA 125 combined for all normal controls
and ovarian cancers (C) for all normal controls and ovarian cancers,
respectively.  indicates the cutoff value of 0.115 that gives a sensitivity
of 73.1%, a specificity of 80.8%, and likelihood ratio (LR) of 4.4 in
Ep-CAM autoantibody.
Fig. 7 Bivariate plot of combined Ep-CAM autoantibody and CA 125
(on log scales) in the sera of ovarian cancer F: normal (n  26); Œ:
cancer (n  52). The oblique line illustrates the separation that can be
achieved between case patients and control subjects by the multiple
logistic analysis using both Ep-CAM and CA 125. The combined cutoff
line was 5.23  33.84Ep-CAM 0.04CA 125, which gave the
sensitivity 47 of 52  90.4% (95% CI, 82.4%  98.4%) and specificity
24 of 26  92.3% (95% CI, 82.1%  100%), respectively.
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detection ratio in ovarian cancer in addition to CA 125 with
unsatisfactory detection rate in early disease. CA 125 is
elevated in several kinds of benign diseases, such as endo-
metriosis and benign ovarian tumor. This experiment showed
14 cases (53.8%) positivity in CA 125 but 6 cases (23.1%) in
Ep-CAM autoantibody in benign diseases experiment (data
were not shown in result section). It means that false positive
ratio can be decreased by way of Ep-CAM autoantibody in
the screening of ovarian cancer. Nevertheless, a large study
with more cases and controls needs to be performed to
confirm the potential diagnostic value of Ep-CAM auto-
antibody.
In conclusion, this investigation has demonstrated the po-
tential value of the cDNA microarray analysis in identifying
overexpressed genes in ovarian cancer, and suggests that Ep-
CAM autoantibody is associated with ovarian cancer and may
be valuable biomarker after population-based research as-
sessing.
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